Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes will comply with the requirements of the protocol;~* Written informed consent obtained from the subject;~* A male or female aged 50 years or older at the time of the first vaccination;~* Female subjects of non-childbearing potential may be enrolled in the study;~For this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.~OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 days prior to vaccination, and has a negative urine pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series;~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period;~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product;~* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy;~* History of HZ;~* Previous vaccination against varicella or HZ;~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation;~* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study;~* Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period;~* Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine;~* Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study;~* Acute disease and/or fever at the time of enrollment;~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Pregnant or lactating female;~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GSK1437173A group (Type: EXPERIMENTAL): Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
- Placebo group (Type: PLACEBO_COMPARATOR): Subjects will receive NaCl solution placebo according to a 0, 2-month schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete